|
Basic Characteristics of Mutations
|
|
Mutation Site
|
L516M |
|
Mutation Site Sentence
|
Two new HCMV-mutations, the UL54-mutation L516M and the UL97-mutation A613V, were characterized by this method. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
UL97 |
|
Standardized Encoding Gene
|
UL97
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
-
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
24120366
|
|
Title
|
Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation
|
|
Author
|
Fischer L,Laib Sampaio K,Jahn G,Hamprecht K,Gohring K
|
|
Journal
|
Antiviral research
|
|
Journal Info
|
2013 Dec;100(3):575-7
|
|
Abstract
|
In transplant recipients, drug-resistant human cytomegalovirus (HCMV) infections remain a serious problem. Drug-resistance against ganciclovir (GCV), cidofovir (CDV) and foscarnet (PFA) is caused by mutations either in the phosphotransferase-gene (UL97) or in the viral polymerase (UL54). For characterization of newly emerging mutations marker transfer analysis is required. Two new HCMV-mutations, the UL54-mutation L516M and the UL97-mutation A613V, were characterized by this method.
|
|
Sequence Data
|
-
|